FindTrial
Sign In

Phase II open label study of CT-2106 as a single agent in patients with advanced metastatic ovarian cancer who have failed one prior platinum and taxane based regimen

Phase II open label study of CT-2106 as a single agent in patients with advanced metastatic ovarian cancer who have failed one prior platinum and taxane based regimen

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
EU CTR
Registry ID
EUCTR2004-001457-28-IT
Enrollment
Unknown
Registered
2005-01-03
Start date
2004-09-09
Completion date
Unknown
Last updated
2012-03-19

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Treatment of patients with advanced ovarian cancer who have failed one prior platinum and taxane based regimen MedDRA version: 6.1 Level: PT Classification code 10057529

Interventions

Product Name: acido poli-L-glutammico-glicina-camptotecina coniugato Product Code: CT2106 Pharmaceutical Form: Powder for infusion* CAS Number: NA Current Sponsor code: CT2106 Concentration unit: mg m

Sponsors

CELL THERAPEUTICS EUROPE
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: Are the trial subjects under 18? no Number of subjects for this age range: F.1.2 Adults (18-64 years) yes F.1.2.1 Number of subjects for this age range F.1.3 Elderly (>=65 years) yes F.1.3.1 Number of subjects for this age range

Exclusion criteria

Exclusion criteria:

Design outcomes

Primary

MeasureTime frame
Main Objective: ;Secondary Objective: ;Primary end point(s):—

Countries

Italy, United Kingdom

Outcome results

None listed

Source: EU CTR (via WHO ICTRP) · Data processed: Feb 4, 2026